Trial reportNeurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology2009
Efficacy of Ginkgolide B in the prophylaxis of migraine with aura.
Trial report in Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 70 citations in OpenAlex.
- The efficacy of ginkgolide B in the acute treatment of migraine aura: an open preliminary trial.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2013Trial
- Gingkolide B as migraine preventive treatment in young age: results at 1-year follow-up.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2011Trial
- Ginkgolide B complex efficacy for brief prophylaxis of migraine in school-aged children: an open-label study.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2011Trial
- Bridging Gaps in Migraine Management: A Comprehensive Review of Conventional Treatments, Natural Supplements, Complementary Therapies, and Lifestyle Modifications.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Role of Phytocompounds for Effective Management of Migraine: Current and Future Prospectives.Central nervous system agents in medicinal chemistry · 2025Review
- Preventive treatment response associated with migraine aura subtypes in a Thai population.Frontiers in human neuroscience · 2022Article
- Review
- Phytosomes as Innovative Delivery Systems for Phytochemicals: A Comprehensive Review of Literature.International journal of nanomedicine · 2021Review
- The Use of Antioxidants in the Treatment of Migraine.Antioxidants (Basel, Switzerland) · 2020Review
- Differences in treatment response between migraine with aura and migraine without aura: lessons from clinical practice and RCTs.The journal of headache and pain · 2019Review
- Phytomedicines in the Treatment of Migraine.CNS drugs · 2019Review
- Complementary and Integrative Medicine for Episodic Migraine: an Update of Evidence from the Last 3 Years.Current pain and headache reports · 2019Review
- Usefulness of nutraceuticals in migraine prophylaxis.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2017Review
- Antiphospholipid syndrome (APS) revisited: Would migraine headaches be included in future classification criteria?Immunologic research · 2017Review
- Current Perspectives on the Beneficial Role of Ginkgo biloba in Neurological and Cerebrovascular Disorders.Integrative medicine insights · 2015Review
- Herbal therapy in migraine.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2014Review
- Nutraceuticals safety and efficacy in migraine without aura in a population of children affected by neurofibromatosis type I.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2013Article
- Treating type 2 diabetes mellitus with traditional chinese and Indian medicinal herbs.Evidence-based complementary and alternative medicine : eCAM · 2013Article
- Nutraceutical preparations in childhood migraine prophylaxis: effects on headache outcomes including disability and behaviour.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2012Article
- Migraine and metabolism.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2012Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In a multicentric, open, preliminary trial, we evaluated the use of ginkgolide B, a herbal constituent extract from Ginkgo biloba tree leaves, in the prophylactic treatment of migraine with aura (MA). Fifty women suffering from migraine with typical aura, or migraine aura without headache, diagnosed according to International Headache Society criteria, entered a six-month study. They underwent a two month run-in period free of prophylactic drugs, followed by a four month treatment period (subdivided into two bimesters, TI and TII) with a combination of 60 mg ginkgo biloba terpenes phytosome, 11 mg coenzyme Q 10, and 8.7 mg vitamin B2 (Migrasoll), administered twice daily. A detailed diary reporting neurological symptoms, duration, and frequency of MA was compiled by patients throughout the trial. The number of MA significantly decreased during treatment (from 3.7 +/- 2.2 in the run-in period, to 2.0 +/- 1.9 during TI and to 1.2 +/- 1.6 during TII; Anova for repeated measures: P < 0.0001). There was also a statistically significant decrease in the average MA duration, which was 40.4 +/- 19.4 min during run-in, 28.2 +/- 19.9 during TI, and 17.6 +/- 20.6 during TII. Total disappearance of MA was observed in 11.1% patients during TI and in 42.2% of patients during T2. No serious adverse event was provoked by Migrasoll administration. Ginkgolide B is effective in reducing MA frequency and duration. The effect is clearly evident in the first bimester of treatment and is further enhanced during the second.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.